A role for artificial intelligence in molecular imaging of infection and inflammation

Johannes Schwenck1,2,3*, Manfred Kneilling2,3,4, Niels P. Riksen5, Christian la Fougère1,3, Douwe J. Mulder7, Riemer J. H. A. Slart6,8 and Erik H. J. G. Aarntzen9

Abstract

The detection of occult infections and low-grade inflammation in clinical practice remains challenging and much depending on readers' expertise. Although molecular imaging, like [18F]FDG PET or radiolabeled leukocyte scintigraphy, offers quantitative and reproducible whole body data on inflammatory responses its interpretation is limited to visual analysis. This often leads to delayed diagnosis and treatment, as well as untapped areas of potential application. Artificial intelligence (AI) offers innovative approaches to mine the wealth of imaging data and has led to disruptive breakthroughs in other medical domains already. Here, we discuss how AI-based tools can improve the detection sensitivity of molecular imaging in infection and inflammation but also how AI might push the data analysis beyond current application toward predicting outcome and long-term risk assessment.

Introduction

Artificial intelligence (AI) is considered to be the key to precision medicine and transforming health care (Denny and Collins 2021). In line with other imaging disciplines, such as microscopy (Meijering et al. 2016) and pathology (Colling et al. 2019; Laak et al. 2021), images obtained from routine clinical procedures represent rich and mineable datasets on specific tissue characteristics (Gillies et al. 2016; Aerts et al. 2014). This realization urged the development of AI-based technologies to exploit these healthy data sources (Parmar et al. 2018; Hosny et al. 2018). Although practical issues concerning data sharing, data safety and standardization are yet to be resolved (He et al. 2019; Currie and Hawk 2021), ongoing developments in AI will drive its implementation in the field of medical imaging (Currie and Rohren 2021). When it comes to application of AI-based technology for nuclear imaging modalities such as positron emission tomography (PET) and single-photon emission tomography (SPECT), excellent reviews which discuss modality-specific potential and limitations are available from the recent literature (Hatt et al. 2021; Uribe et al. 2019; Zukotynski et al. 2021; Decuyper et al. 2021). A key asset of nuclear imaging modalities is their whole body field-of-view and hence the capacity to quantify the distribution of tracers targeting specific biological processes where several organs and tissues are involved. Furthermore, dynamic imaging in nuclear
medicine offers the possibility to temporally resolve systemic processes. Both aspects of nuclear imaging are extremely useful to develop a ‘systems biology’ approach based on nuclear imaging to characterize host’ immune responses in infection and inflammation.

AI methodology is evolving rapidly and it is beyond the scope of this review to provide a comprehensive overview on current concepts in image analysis. In general, AI-based approaches can be divided into supervised and unsupervised learning methods. Supervised learning requires data which is considered a ground truth or a gold standard, like histopathology. Supervised learning therefore is a mathematical way to approximate a model using a labeled training dataset which is then optimized in iterative steps. Typically, validation and test datasets are needed to assess the accuracy of the developed model. Unsupervised learning is trained to recognize patterns in unlabeled data without ground truth information. In unsupervised learning, algorithms are searching for regularities that can be used to define relationships like groups with similar features in an unlabeled dataset. Furthermore, unsupervised learning methods are used for capturing noise in data or to generate new data samples. Clustering methods like k-means are common unsupervised approaches to find patterns between data points in a dataset. More sophisticated approaches use, for example, trained neural networks which allow to model more complex relationships with only little assumptions (LeCun et al. 2015).

While in its early days, now is the time to also consider the potential roles of AI specifically in molecular imaging of infection and inflammation. ‘Precision medicine’ in the field of inflammation translates to early identification of patients at risk for inflammatory diseases and tailored treatment duration based on individual characteristics of a patients’ immune system.

In recent years it became evident that the activation of the immune system requires metabolic reprogramming, especially in regard to glucose metabolism (Gaber et al. 2017), thus in principle leads to effects measurable with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) PET. Likewise, the spatial distribution of immune cells throughout the body determines the effectiveness of immune responses, which is assessable, for example, by radiolabeled leukocyte scintigraphy. While extensively studied in the aspect of cancer immunotherapy, these effects are similarly important in inflammatory diseases including infections, autoimmune disorders and atherosclerosis.

An important aspect of inflammation is the emerging concept of trained immunity: long-term functional reprogramming of the innate immune cells which co-determines responses to subsequent triggers (Netea et al. 2020a; Schultze et al. 2018). The development of trained immunity is determined by epigenetic reprogramming and profound rewiring of metabolic circuits in immune cells.

Current routine analysis of imaging techniques like [18F]FDG PET or radiolabeled leukocyte scintigraphy rely on the visual detection of foci in symptomatic patients, which heavily depends on the readers’ reference. Given the pivotal role of metabolic reprogramming in a range of inflammatory conditions, it emerges that at present only the tip of the iceberg of the available information is extracted out of the acquired data.

The recent advances in AI might push the analysis of current imaging techniques toward a more comprehensive understanding of inflammatory diseases including atherosclerosis and infections, to the detection of pathological immune responses even in asymptomatic patients on the long run.
In this short communication we propose three potential tasks for AI, ranging from practical to more hypothetical, where AI-based technologies can be applied to improve current practice.

Artificial intelligence to improve detection
Over the past years, $^{[18F]}$FDG PET/CT has established its central role in the diagnosis and follow-up of infectious diseases and inflammatory conditions (Slart et al. 2018a; Signore et al. 2019; Chakfe et al. 2020; Jamar et al. 2013). Based on the high sensitivity and favorable whole-body view, the range of clinical indications continues to expand and the questions to be addressed are increasingly complex. At these far-end applications in inflammation imaging, current PET technologies have probably met their limits of detection and discriminative power (Fig. 1).

This holds true particularly for infections at occult sites, low-grade infections or low-grade inflammatory conditions that are diagnosed late and treated with delay (Hipfl et al. 2021; Laohapensang et al. 2017; Talha et al. 2020). Although this concerns a minority of patients, these cases consume a lot of health care related services, multiple diagnostic tests are being performed and prolonged treatment is required with increased likelihood to encounter complications. For example, the diagnosis of infectious (native or prosthetic valve) endocarditis currently requires a composite of clinical, microbiological and imaging (ultrasound and $^{[18F]}$FDG PET) to accomplish reasonable sensitivity and specificity (Chakfe et al. 2020; Habib et al. 2015). However, this investment in diagnostic accuracy is mandatory as we have learned that insufficient treatment of even these small intravascular infectious foci is associated with increased mortality (Jaltotage et al. 2021; Chirillo 2021).

Moreover, in the premise of ‘precision medicine,’ (intravenous) antibiotic treatment durations tend to be shortened (Berrevoets et al. 2019; Kouijzer et al. 2021) to avoid

![Fig. 1 Artificial intelligence to improve detection. A graphical illustration of the typical dynamics of an immune response upon a trigger, with rapid increase, associated with increased glycolysis in effector cells which can be measured by $^{[18F]}$FDG PET and expressed as maximum or mean standardized uptake values (SUVmax/mean). As soon as the causative trigger is cleared, inflammatory responses also include repair processes to gradually return to a state of tissue homeostasis](image)
overtreatment and reduce health care expenditure. Thus, discriminating persistent foci of active infection from tissue remodeling at the end of antibiotic or anti-inflammatory treatment will be an increasingly relevant, but challenging task for $^{18}$F]FDG PET imaging.

As there is a need for improved detection of low-grade or localized infections, which inherent features of nuclear imaging techniques are limiting? In comparison with computed tomography (CT) nuclear imaging techniques suffer from long acquisition times, inherently resulting in motion artifacts. Furthermore, nuclear imaging is constraint by radiation dose and the associated safety considerations, which together with the urge to detect low-grade of localized infection, call for further optimization of detection efficiency of PET and SPECT systems. The introduction of new PET scanners with digital detector technology and a long-axial field of view of 100 cm or more provide significant improvements in this regard. These developments have the potential to significantly reduce the data acquisition times in PET, which makes a high-resolution whole-body PET scan in less than 5 min possible (Alberts et al. 2021; Filippi and Schillaci 2022). Besides that, the substantial advances of this generation of scanners also allow a better temporal and spatial resolution as well as reduction of the administered radiation dose.

The relatively poor spatial resolution of PET (3–4 mm) and SPECT (8–9 mm) hampers the accurate assessment of anatomical regions with respiratory and cardiac motion. This is particularly relevant for imaging subtle changes in signal intensity in the myocardium, for example when endocarditis is suspected; or discrimination of $^{18}$F]FDG uptake in aortic root complications after recent vascular graft surgery.

Cardiac and respiratory motion, however, are highly standardized movements that can be modelled using AI-based technologies (Fig. 2). These are particularly suited to reconstruct images by incorporating previously learned information that compensates for motion. Indeed, data-driven approaches for PET image reconstruction that compensates for respiratory motion are increasingly available (Buther et al. 2016; Feng

![Fig. 2](potential AI workflow to improve image quality by cardiac and respiratory motion correction. The pre-learned, highly standardized movements of the heart and the lung can be integrated in the image reconstruction in order to optimize the image quality leading to advantages in the visual assessment by the nuclear medicine physician)
et al. 2019; Schleyer et al. 2011), paralleling developments in CT (Saeedan et al. 2021). Previously, electrocardiogram (ECG)-gated motion correction of $[^{18}\text{F}]-\text{NaF}$ uptake in coronary arteries in patients with myocardial infarction or stable angina had significant impact on lesion quantification (Rubeaux et al. 2016). Along the same line for endocarditis, more accurate detection of small infectious foci in the plane of cardiac valves would increase detection rates and allow better co-localization with findings on ultrasound or cardiac CT, which improves diagnostic accuracy (Hove et al. 2021).

On a more general note, deep-learning methods to reconstruct whole body PET images without the signal-derived input for attenuation and scatter correction by its CT component are reported (Yang et al. 2021; Haggstrom et al. 2019), with non-inferior image quality, but much faster reconstruction times. Although large-scale comparative studies supporting AI-based motion correction are lacking, these approaches demonstrated that pre-learned information can be incorporated in AI-based reconstructions of PET acquisitions.

In addition to factors that affect the measured signal intensity, the presence of noise in PET and SPECT data impairs accurate visual assessment and diagnostic accuracy of scan images in low-count statistics and the detection of small foci with little signal-to-noise ratio (Minarik et al. 2020). For example, radiolabeled autologous leukocytes for SPECT imaging have long been used to detect infectious foci and with sufficient specificity to discriminate infection from inflammation (de Vries et al. 2010; Roca et al. 2010). However, its inferior image quality due to low-count statistics and high levels of noise resulted in a rapid take-over by $[^{18}\text{F}]}$FDG PET/CT for these indications (Jamar et al. 2013), as image quality and system sensitivity were preferred despite the use of a less specific tracer. AI-based technologies can be exploited to reduce noise in such settings, which will positively impact image interpretation. For PET imaging the assignment of a line-of-response (LOR) for accurate image reconstruction can be corrupted by non-perpendicular coincidences, resulting in uncertainties in positioning the input signal. A deep learning estimator has been developed to predict the depth-of-interaction of incoming photons in pixelated detectors, which resulted in improved performance (Zatcepin et al. 2020). Improved positioning of input signals for monolithic detectors has been improved using convolutional neural networks that integrates the charge of silicon photomultipliers to predict locations of non-perpendicular coincidences (He et al. 2021). Compton scattering in the detection crystal results in incorrectly assigned LORs and contributes to system noise for PET and SPECT imaging. Deep learning algorithms trained on Monte Carlo simulation data showed improved LOR recovery rates and sensitivity by including accurate position of events in image reconstruction (Bergeron et al. 2014). Furthermore, in PET imaging, prediction of adverse cardiovascular events has recently been studied through the implementation of transfer learning, which allows for data economization while boosting image recognition capabilities and broadening the horizon of network architectures that can be constructed (Vos et al. 2019).

Image denoising based on deep learning methods is applied in general image restoration in cases of low or lack of spatial input. Several studies have now shown potential to convert low-count to high-count PET or SPECT images using U-Net (Kaplan and Zhu 2019; Dietze et al. 2019) or ResNet (Gong et al. 2019; Cui et al. 2019)
algorithms. Lastly, on the hardware site of development, the new generation of long-axis field-of-view PET scanners have an even better sensitivity (Alberts et al. 2021; Badawi et al. 2019) which can also be exploited to increase signal-to-noise ratio.

**Artificial intelligence to predict outcomes**

Immune responses are a complex series of events that involve different immune cell populations and requires a concerted action in multiple body compartments (Spitzer et al. 2017; Chavakis et al. 2019). For example, upon infection, inflammatory monocytes are recruited from the bone marrow and spleen and increased myelo- and granulopoiesis should compensate for the loss of these effector cells in peripheral tissues (Hotchkiss et al. 2016). Indeed, most patients referred for nuclear imaging under suspicion of an infectious or inflammatory condition have symptoms and clinical signs indicative of systemic immune responses, such as fever, increased C-reactive protein and erythrocyte sedimentation rate and leukocytosis. The questions here are whether we can capture these systemic responses using molecular imaging and use this information to improve outcome prediction (Fig. 3).

The switch from a quiescent to an activated status inevitably comes with metabolic reprogramming of immune cells, resulting in increased glycolytic capacity (Netea et al. 2020a; Arts et al. 2017, 2018). As $[^{18}F]$FDG-PET is a highly sensitive technique to quantify glycolysis on a whole-body scale, we and others have demonstrated that increased uptake of $[^{18}F]$FDG-PET in organs involved in hematopoiesis and immune activation, e.g., bone marrow, spleen and vascular system, associates with the state of immune activation (van der Heijden et al. 2020; Bernelot Moens et al. 2016; Valk et al. 2016; Joseph et al. 2017; Stiekema et al. 2019; Ungar et al. 2020; Kalafati et al. 2020). Paralleling mechanisms might also play a role in the responsiveness of immune cells in anticancer immunity (Kalafati et al. 2020; Netea and Joosten 2018; Schwenck et al. 2020; Seith et al. 2020). Increased $[^{18}F]$FDG uptake in bone marrow or spleen, as substrate of systemic immune activation, are associated with improved clinical outcome in melanoma patients under immune checkpoint inhibitors (Seban et al. 2021). This effect could potentially also be
observed in overacting autoimmune events by $[^{18}\text{F}]$FDG PET (Spitzer et al. 2017; Kalafati et al. 2020; Flint et al. 2017).

In patients with atherosclerotic cardiovascular diseases there is already evidence that increased $[^{18}\text{F}]$FDG uptake in the arterial wall, spleen and bone marrow predicts future occurrence of cardiovascular events (Emami et al. 2015). To the contrary, clinical studies in sepsis showed that patients with decreased glycolytic capacity in leukocytes have a worse clinical outcome (Cheng et al. 2016; Hotchkiss et al. 2013; Kaufmann et al. 2018), a phenomenon called ‘immune paralysis.’

Thus, as the whole-body field of view of PET allows to assess body compartments involved in the systemic response to infection or inflammation, which element hampers the analysis of these potentially predictive data? At present, the integration of this additional data on immune metabolism in multiple body compartments depends on the limited human capacity to deal with multi-dimensional data. Systems biology studies are integrating large-scale (‘omics’) data, e.g., from different tissues (Kidd et al. 2014) and therefore are urged to implement AI-based technologies for data analysis (Camacho et al. 2018). These studies enabled a more comprehensive mechanistic insight in multidimensional complex diseases (Yang 2020), such as cardiovascular disease (Lempainen et al. 2018; Makinen et al. 2014; Shu et al. 2017; Slart et al. 2021). These studies demonstrated that the net outcomes on patient level result from perturbations in multiple body compartment involving diverse cell types and molecular pathways. The integration of these different scales of data, in which the contribution of the individual components can vary from subject to subject, demonstrates that cardiovascular disease is promoted by increased inflammatory pathways in the liver, adipose tissue and vascular system (Libby et al. 2019), as well as by the immune response, which is not limited to the arterial wall as it is also detectable in the bone marrow and the spleen.

Similar to infections, effective anticancer immune responses require an integrated action from both innate and adaptive immune cells (Chiossone et al. 2018) including their activation in local and distant body compartments (Spitzer et al. 2017; Kalafati et al. 2020). These observations underscore the general concept that on a systems level, metabolism and immune responses are connected (Flint et al. 2017).

Thus, immune metabolism is a preeminent example of reciprocal interactions on a cellular, organ and system level (Lercher et al. 2020) that impact inflammatory and infectious diseases as well as the homeostasis of the immune system, as will be discussed later. $[^{18}\text{F}]$FDG PET is well-suited to measure metabolic activity across these multiple circuitries, provided that AI-based technologies are developed to extract and process these data in predictive models (Fig. 4).

**Artificial intelligence to provide prognostic information**

Pathogen and damage-associated molecular patterns are sensed by cells of the innate immune system, inducing rapid activation and non-specific responses to eliminate the trigger. A growing body of evidence suggests that, in addition to these rapid ‘first line-of-defense’ responses, long-term functional reprogramming of innate immune cells occurs and co-determines responses to subsequent triggers. So, ‘immunological memory’ is no longer considered to be exclusive for cells of the adaptive immune system, but also occurs in innate immune cells, both in hematopoietic progenitor cells (central trained
immunity) and in differentiated cells such as monocytes, macrophages and natural killer cells (peripheral trained immunity) (Netea et al. 2020a; Schultze et al. 2021). These ‘trained immunity’ phenotypes have implications for the response to future infections (Netea et al. 2020b). Central in the development of trained immunity is epigenetic reprogramming, which is closely intertwined with metabolic reprogramming, characterized by an increased glycolysis, glutaminolysis and mevalonate pathway, among others. This mechanism allows altered immune-metabolic circuits in immune cells to respond with faster and higher upregulation of aerobic glycolysis and subsequent cytokine production capacity upon subsequent infectious triggers (Dominguez-Andres and Netea 2019).

Environmental inflictions, and the associated inflammatory response on tissue level, culminate during life span and are considered an integral part of ageing (Lopez-Otin et al. 2013; Sugimoto et al. 2019). It is tempting to speculate that beyond the development of whole body $[^{18}\text{F}]$FDG PET as a predictive imaging classifier based on immune metabolic phenotypes, there might be a prognostic role for $[^{18}\text{F}]$FDG PET to determine long-term outcome associated with chronic inflammatory conditions (Fig. 5).

In addition to trained immune cells, repetitively triggered stromal cells can also convert into a state of chronic low-grade inflammation (Bekkering et al. 2016a, b, 2018, 2019; Leentjens et al. 2018), with detrimental impact on long-term clinical outcomes. For example, endothelial cells of the vascular system, which are key in directing the trafficking of immune cells to inflamed tissues, also respond to systemic inflammatory mediators (Pober and Sessa 2007). Moreover, these endothelial cells are exposed to a multitude of noxes throughout a lifespan, e.g., hypercholesterolemia or hyperglycemia, inducing cell damage and low-grade inflammation aimed to maintain endothelial integrity. The role of $[^{18}\text{F}]$FDG PET imaging in large vessel vasculitis is established (Jamar et al. 2013; Slart et al. 2018b) and is currently explored for chronic inflammatory conditions (van der Heijden et al. 2020; Noz et al. 2020; Valk et al. 2017). Defining a threshold

![Fig. 4](image-url)
on this sliding scale from overt vascular wall inflammation, e.g., in the context of vasculitis, associated with symptoms and representing a clinical entity, to low-grade inflammation, associated with chronic inflammatory conditions such as atherosclerosis, perhaps is a new prognostic task for $[^{18}\text{F}]$FDG PET that comes within reach with the advent of AI-based technologies (Fig. 6). Here the gain in image quality of new digital PET scanners and especially of the recently introduced long-axis field of view PET scanner might favor the evaluation of vascular wall inflammation by PET, as it allows to acquire dynamic data that can provide more accurate quantification of the biological process, in this case $[^{18}\text{F}]$FDG uptake rates in cell types involved in vascular wall inflammation. Secondly, it can assess the involvement of primary and secondary lymphoid organs throughout the whole body in systemic diseases versus tissue-confined local inflammatory process.
Similarly, as defects in metabolism are commonly associated with impaired outcomes in various conditions, such as impaired regulation of glucose homeostasis in type 2 diabetes (Bernelot Moens et al. 2016; Lee et al. 2018; Hotamisligil 2017; Norata et al. 2015) or obesity in anticancer immunity (Thaiss et al. 2021; Ringel et al. 2020) and atherosclerosis (Bucerius et al. 2012, 2014), such prognostic role might be requested from $[^{18}\text{F}]$ FDG by clinical disciplines in the near future. As far as it concerns the immune system, this field is actively researched to develop therapeutic strategies (Mulder et al. 2019) to enhance or reduce inflammatory responses in anticancer immunity (Priem et al. 2020), autoimmune (Municio and Criado 2020) and infectious diseases (O’Neill and Netea 2020; Netea et al. 2020c). The higher sensitivity of the whole-body PET scanner enables the acquisition of low-dose PET images below 1–1.5 mSv, allowing its more frequent use in non-oncologic diseases for risk stratification assessment.

How should AI-based technologies be implemented to facilitate the development of $[^{18}\text{F}]$FDG PET as a tool to determine prognostic immune metabolic profiles? The challenge in such task lies in the discrimination of \textit{bona fide} inflammation from \textit{mala fide} inflammation. This difference is expected to be subtle, as the inflammatory response in a distinct context of disease is beneficial rather than pathological, and temporally apart from an identified trigger.

Accurate appraisal of subtle differences requires large datasets for training and supporting ‘circumstantial evidence’ where possible. For example, it can be postulated that assessment of $[^{18}\text{F}]$FDG uptake in the vascular wall as \textit{mala fide} will be more accurate if not only metabolic activity in the hematopoietic system is taken into account, but also atherosclerotic calcifications and body composition in terms of subcutaneous and visceral adipose tissue versus muscle mass can be deduced from the low-dose CT (Laur et al. 2021) and incorporated in the risk assessment. Similarly, AI-algorithms are available to assess bone mineralization and emphysema score on low-dose CT (Ebrahimian et al. 2021), which could determine the host’ long-term responses to environmental inflictions like smoking. As for now, such information is not incorporated in current practice yet. Along with training AI-algorithms on large datasets come the need for harmonization, smart processing and modelling, each individual task is suited for AI-based technologies. In line with developments in CT imaging (Choe et al. 2019), AI-based algorithms can be trained to overcome center- or vendor-related differences in reconstruction settings (Arabi and Zaidi 2021) and allowing to extract radiomic features (Orlhac et al. 2018; Zwanenburg 2019).

Reiterating from the conceived potential of AI to transform healthcare (Denny and Collins 2021), contemplating whole body $[^{18}\text{F}]$FDG PET images as huge interoperable datasets that meet the criteria of diversity and inclusion, implies that we need AI-technology to open up these big datasets and exploit its potential to approach immune metabolism on a systems level in clinical settings.

**Challenges and potential solutions**

Despite the sheer limitless methodological and technological advancements in AI-based technology, the widespread application of AI-tools in molecular imaging of infection and inflammation is facing some major challenges on its way into routine clinical use. One hurdle that will need to be overcome is to deal with the ‘black box’ stigma on
AI-based algorithms; the lack of explainable correlations between in- and output leaves physicians often hesitant to rely on AI-based output. In addition, the subtle differences between physiological and pathological and potentially high variations between individual patients requires large datasets and/or labeled datasets based on ground truth, of which the latter is more difficult as it will require invasive procedures to obtain tissue samples to analyze immune cells’ metabolic profiles.

To address these issues, smaller studies with high translational design including flow cytometry, metabolomics and/or transcriptomic data from circulating immune cells or the hematopoietic system could provide proof-of-concept to correlate specific imaging findings to immune metabolic features in relevant cell populations (e.g., Hotchkiss et al. 2016). Subsequent studies can then build further upon these data and provide larger datasets for validation and to determine its value in real-life clinical setting. For such studies with large datasets, questions on harmonization of input data arise, which have partly been tackled in the EARL program for multicenter studies by the European Association for Nuclear Medicine. Moreover, computing higher order features from PET requires image normalization during data processing and training AI-based models on a wide range of scanner hardware can provide a solution that would be compatible with current deep-learning networks, provided that the computing power is sufficient. Nevertheless, the input for predictive or prognostic AI-based models as discussed in this communication should be ‘supervised’ as only PET parameters computed from predefined immune relevant organ systems, in line with current concepts on immune-metabolism, should serve as input data.

Another challenge will be the integration of the clinical experience from the nuclear medicine and radiology readers into a future AI-supported workflow of clinical decision making. The experience of the reader, who is also taking the case-specific clinical context into account, will be difficult to replace. Therefore at least in the coming few years, AI might support the clinical decisions if it is confirming the evaluation by the reading physician, but it is unclear how to proceed if human and AI-based assessment are coming to the contradictory results. In line with broader developments of AI-based technology in medical imaging, liability issues need to be addressed in the near future.

Conclusion
AI tools are increasingly used for a growing number of tasks in the imaging field ranging from technical applications which improve the sensitivity of scanners to biomedical applications for holistic data analysis. As proposed above, AI has the potential to improve the detection of inflammatory diseases and predict prognosis and outcome of patients under various immune-mediated conditions (Table 1). Furthermore, these tools are capable to provide a deeper understanding of the basic molecular mechanisms of inflammatory diseases.

For a successful application in future health care in the context of personalized medicine the tight integration of the AI imaging tools with other diagnostic methods like genetic analysis, proteomics and metabolomics is the key to achieve reliable and impactful data which improves treatment decisions and ultimately patients’ well-being and survival.
Table 1  Key elements for the future: opportunities, challenges and solutions of AI in infection and inflammation molecular imaging

| Opportunities                              | Challenges                                      | Solutions                                                                 |
|--------------------------------------------|-------------------------------------------------|---------------------------------------------------------------------------|
| Improve detection                          | Detection of low-grade or localized infections   | Cardiac and respiratory motion correction                                 |
|                                            | Insufficient spatial resolution                  | Improving of the detector sensitivity: e.g., by predicting the depth-of-interaction of incoming photons |
|                                            | Lack of sensitivity                              | Image denoising by AI                                                     |
|                                            | Long acquisition times                           |                                                                           |
|                                            |                                                  |                                                                           |
| Predict outcomes                           | Prediction of individual outcome by assessing the systemic immune response | In depth analysis of high-dimensional imaging data by AI algorithms        |
|                                            | Validated data derived from multiple organ systems required |                                                                           |
|                                            |                                                  |                                                                           |
| Provide prognostic information             | Imaging as predictive classifier to determine long-term outcome | AI analysis on big data provided by, e.g., large multicenter studies or national health care providers |
|                                            | Discrimination of physiological vs. pathological immune metabolic pathways |                                                                           |
|                                            | Subtle differences require large datasets for training |                                                                           |
|                                            | High efforts for data harmonization              |                                                                           |

Abbreviations
AI: Artificial intelligence; CT: Computed tomography; [(18F)FDG: 2-[(18F)fluoro-2-deoxy-D-glucose]; LOR: Line-of-response; MRI: Magnetic resonance imaging; PET: Positron emission tomography; SPECT: Single-photon emission tomography; SUV: Standardized uptake value.

Author contributions
EA developed the overall concept of the review. EA and JS wrote the manuscript. MK, NR, CF, UM and RS critically read and amended the manuscript. All authors read and approved the final manuscript.

Funding
N.P.R. is funded by an IN-CONTROL CVON grant (CVON2018-27) of the Netherlands Heart Foundation, and a JTC2018 grant (‘MEMORY’) from the European Research Area Network on Cardiovascular Disease (ERA-CVD).

Availability of data and materials
None.

Declarations

Ethics approval and consent to participate
None.

Consent for publication
None.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, Tübingen, Germany.
2Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University, Röntgenweg 13, 72076 Tübingen, Germany.
3Cluster of Excellence iFIT (EXC 2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’; Eberhard Karls University, Tübingen, Germany.
4Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
5Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
6Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
7Department of Biomedical Photonic Imaging, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.
8Department of Medical Imaging, Radboud University Medical Center, Nijmegen,
The Netherlands. *Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Received: 7 February 2022   Accepted: 16 May 2022
Published online: 01 September 2022

References

Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006

Alberts I, Hunemann JD, Prensogil G, Mingels C, Bohn KP, Viscione M et al (2021) Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT. Eur J Nucl Med Mol Imaging 48(8):2395–2404

Arabi H, Zaidi H (2021) Non-local mean denoising using multiple PET reconstructions. Ann Nucl Med 35(2):176–186

Arts RJ, Gresnigt MS, Joosten LA, Netea MG (2017) Cellular metabolism of myeloid cells in sepsis. J Leukoc Biol 101(1):151–164

Arts RJW, Mooring S, Novakovic B, Li Y, Wang SY, Oosting M et al (2018) BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 21(3):189–100.e5

Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM et al (2019) First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med 60(3):299–303

Bekkering S, Blok BA, Joosten LA, Riksen NP, van Crevel R, Netea MG (2016a) In vitro experimental model of trained innate immunity in human primary monocytes. Clin Vaccine Immunol 23(12):926–933

Bekkering S, van den Munckhof J, Nielen T, Lamfers E, Dinarello C, Rutten J et al (2016b) Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis 254:228–236

Bekkering S, Arts RJW, Novakovic B, Kourtzelis I, van der Heijden C, Li Y et al (2018) Metabolic induction of trained immunity through the mevalonate pathway. Cell 172(1–2):135–46.e9

Bekkering S, Stiekema LCA, Bernelot Moens S, Verweij SL, Novakovic B, Prange K et al (2019) Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab 30(1):1–2

Bergeron M, Cadorette J, Tetrault MA, Beaudoin JF, Leroux JD, Fontaine R et al (2014) Imaging performance of LabPET APO-based digital PET scanners for pre-clinical research. Phys Med Biol 59(3):661–678

Bernelot Moens SJ, Steenkenbroek RM, van der Valk FM, Verweij SL, Koelemay MJ, Verberne HJ et al (2016) Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study. BMC Cardiovasc Disord 16(1):237

Berrevoets MAH, Kourijer UE, Sliker K, Aarnetzen E, Kulberg BJ, Oever JT et al (2019) (18)F-FDG PET/CT-guided treatment duration in patients with high-risk Staphylococcus aureus bacteremia: a proof of principle. J Nucl Med 60(7):998–1002

Bucerius J, Mani V, Moncieff C, Rudd JH, Machac J, Fuster V et al (2012) Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol 59(23):2080–2088

Bucerius J, Mani V, Wong S, Moncieff C, Izquierdo-Garcia D, Machac J et al (2014) Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging 41(5):934–945

Butcher F, Vethren T, Scharpf KP, Scharpf M (2016) Impact of data-driven respiratory gating in clinical PET. Radiology 281(1):229–238

Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ (2018) Next-generation machine learning for biological and clinical applications. Eur J Vasc Endovasc Surg 59(3):339–384

Chavakis T, Mitroulis I, Hajishengallis G (2019) Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nat Immunol 18(11):671–688

Cheng SC, Scicluna BP, Arts RJ, Gresnigt MS, Lachmandas E, Giamarellos-Bourboulis EJ et al (2016) Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol 17(4):406–413

Chiiossone L, Dumas PY, Vienne M, Vivier E (2018) Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 18(11):671–688

Chirillo F (2021) New approach to managing infective endocarditis. Trends Cardiovasc Med 31(5):277–286

Choe J, Lee SM, Do KH, Lee G, Lee JG, Lee SM et al (2019) Deep learning-based image conversion of CT reconstruction kernels improves radiomics reproducibility for pulmonary nodules or masses. Radiology 292(2):365–373

Colling R, Pitman H, Oien K, Rajpoot N, Macklin P, Group CM-PAHW et al (2019) Artificial intelligence in digital pathology: a roadmap to routine use in clinical practice. J Pathol 249(2):143–150

Cui J, Gong K, Guo N, Wu C, Meng X, Kim K et al (2019) PET image denoising using unsupervised deep learning. Eur J Nucl Med Mol Imaging 46(13):2780–2789

Currie G, Hawk KE (2021) Ethical and legal challenges of artificial intelligence in nuclear medicine. Semin Nucl Med 51(2):120–125

Currie G, Rohren E (2021) Intelligent imaging in nuclear medicine: the principles of artificial intelligence, machine learning and deep learning. Semin Nucl Med 51(2):102–111

de Vos BD, Berendsen FF, Viergever MA, Sokoost H, Staring M, Isgum I (2019) A deep learning framework for unsupervised affine and deformable image registration. Med Image Anal 52:128–143
Leentjens J, Bekkerling S, Joosten LAB, Netea MG, Burgner DP, Riksen NP (2018) Trained innate immunity as a novel mechanism linking infection and the development of atherosclerosis. Circ Res 122(5):664–669

Lempiainen H, Braenne I, Michael T, Tragante V, Vilne B, Webb TR et al (2018) Network analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targets. Sci Rep 8(1):3434

Lencer A, Baazim H, Bergthaler A (2020) Systemic immunometabolism: challenges and opportunities. Immunity 53(3):496–509

Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS et al (2019) Atherosclerosis. Nat Rev Dis Primers 5(1):56

Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194–1217

Makinen VP, Civelek M, Meng Q, Zhang B, Zhu J, Levian C et al (2014) Integrative genomics reveals novel molecular pathways and gene networks for coronary artery disease. PLoS Genet 10(7):e1004502

Meijering E, Carpenter AE, Peng H, Hamprecht FA, Olivo-Marín JC (2016) Imaging the future of bioimage analysis. Nat Biotechnol 34(12):1250–1255

Minarik D, Enqvist O, Tragardh E (2020) Denoising of scintillation camera images using a deep convolutional neural network: a Monte Carlo simulation approach. J Nucl Med 61(2):298–303

Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG (2019) Therapeutic targeting of trained immunity. Nat Rev Drug Discov 18(7):553–566

Municio C, Criado G (2020) Therapies targeting trained immune cells in inflammatory and autoimmune diseases. Front Immunol 11:631743

Netea MG, Joosten LAB (2018) Trained immunity and local innate immune memory in the lung. Cell 175(6):1463–1465

Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E et al (2020a) Defining trained immunity and its role in health and disease. Nat Rev Immunol 20:375–388

Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E et al (2020b) Defining trained immunity and its role in health and disease. Nat Rev Immunol 20(6):375–388

Netea MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, van Creveld R, van de Veerdonk FL et al (2020c) Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell 181(5):969–977

Norata GD, Caligiuri G, Chavakis T, Materese G, Netea MG, Nicolletti A et al (2015) The cellular and molecular basis of translational immunometabolism. Immunity 43(3):421–434

Noz MP, Bekkerling S, Grol H, Nielen TM, Lamfers EJ, Schlitzer A et al (2020) Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease. Elife. https://doi.org/10.7554/eLife.60939

O'Neill LAJ, Netea MG (2020) BCG-induced trained immunity: can it offer protection against COVID-19? Nat Rev Immunol 20(6):335–337

Orfhac F, Bougdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L et al (2018) A postreconstruction harmonization method for multicenter radiomic studies in PET. J Nucl Med 59(8):1321–1328

Parmar C, Barry JD, Hosny A, Quackenbush J, Aerts H (2018) Data analysis strategies in medical imaging. Clin Cancer Res 24(15):3492–3499

Pober JS, Sessa WC (2007) Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 7(10):803–815

Piem B, van Leent MMT, Teunissen AJP, Sofas AM, Mourtis VP, Willemssen L et al (2020) Trained immunity-promoting nanobiologic therapy suppresses tumor growth and potentiates checkpoint inhibition. Cell 183(3):786–801.e19

Ringel AE, Drijvers JM, Baker GJ, Catozzi A, Garcia-Canaveras JC, Gassaway BM et al (2020) Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell 183(7):1848–1866.e26

Roca M, de Vries EF, Jamar F, Israel O, Signore A (2010) Guidelines for the labelling of leukocytes with (11)In-oxine Inflammation/Infection. Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging 37(4):835–841

Rubeaux M, Joshi NV, Dweck MR, Fletcher A, Motwani M, Thomson LE et al (2016) Data analysis strategies in medical imaging. Clin Cancer Res 22(6):1550–1558

Schwanen J, Schlink T, Muller CA, Reissig C, Scharringhaus V, Rothe R et al (2020) Distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo (18)F-FDG-PET. Theranostics 10(2):925–937

Seban RD, Champion L, Muneer I, Synn S, Schwartz LH, Dercle L (2021) Potential theranostic role of bone marrow glucose metabolism on baseline (18)F-FDG PET/CT in metastatic melanoma. J Nucl Med. https://doi.org/10.2967/jnumed.121.262361

Seif J, Forschner A, Weide B, Guckel B, Schwartz M, Schwenck J et al (2020) Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. https://doi.org/10.1136/jitc-2020-000656

Shu L, Chan KHK, Zhang G, Huan T, Kurt Z, Zhao Y et al (2017) Shared genetic regulatory networks for cardiovascular disease and type 2 diabetes in multiple populations of diverse ethnicities in the United States. PLoS Genet 13(9):e1007040

Signore A, Sconfienza LM, Borens O, Glaudemans A, Cassar-Pullicino V, Trampuz A et al (2019) Consensus document for the diagnosis of prostatic joint infections: a joint paper by the EANM, EBJS, and ESR (with ESCMID endorsement). Eur J Nucl Med Mol Imaging 46(4):971–988

Slatt R, Glaudemans A, Lancelotti P, Hyafil F, Blankstein R, Schwartz RG et al (2018a) A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the
European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology: J Nucl Cardiol 25(1):298–319

Slart R, Williams MC, Juarez-Orozco LE, Rischpler C, Dwivedi MR, Glaudemans A et al (2021) Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT. Eur J Nucl Med Mol Imaging 48(5):1399–1413

Slart R, Writing g, Reviewer g, Members of EC, Members of EI, Inflammation et al (2018b) FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. Eur J Nucl Med Mol Imaging 45(7):1250–1269

Slart R, Williams MC, Juarez-Orozco LE, Rischpler C, Dwivedi MR, Glaudemans A et al (2021) Position paper of the EACVI and EANM on artificial intelligence applications in multimodality cardiovascular imaging using SPECT/CT, PET/CT, and cardiac CT. Eur J Nucl Med Mol Imaging 48(5):1399–1413

Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM et al (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168(3):487-502.e15

Stiekema LCA, Stroes ESG, Verweij SL, Kasahahnu H, Chen L, Wasserman SM et al (2019) Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J 40(33):2775–2781

Sugimoto MA, Vago JP, Parretti M, Teixeira MM (2019) Mediators of the resolution of the inflammatory response. Trends Immunol 40(3):212–227

Talha KM, DeSimone DC, Sohail MR, Baddour LM (2020) Pathogen influence on epidemiology, diagnostic evaluation and management of infective endocarditis. Heart 106(24):1878–1882

Ten-Hove D, Slart R, Sinha B, Glaudemans A, Budde RPJ (2021) (18)F-FDG PET/CT in infective endocarditis: indications and approaches for standardization. Curr Cardiol Rep 23(9):130

Thaiss WM, Gaitidis S, Sartorius T, Machann J, Peter A, Eigentler TK et al (2021) Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients. Cancer Immunol Immunother 70(5):1263–1275

Ungar B, Pavel AB, Robson PM, Kaufman A, Pluzan A, Brunner P et al (2020) A preliminary (18)F-FDG-PET/MRI study shows increased vascular inflammation in moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract 8:3500–3506

Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, Benard F et al (2019) Machine learning in nuclear medicine: part 1—introduction. J Nucl Med 60(4):451–458

van der Heijden C, Smeets EMW, Aarniztegen E, Noz MP, Monajemi H, Kersten S et al (2020) Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism. J Clin Endocrinol Metab. https://doi.org/10.1210/cjcem/dgz306

van der Laak J, Litjens G, Ciompi F (2021) Deep learning in histopathology: the path to the clinic. Nat Med 27(5):775–784

van der Valk FM, Verweij SL, Zwinderman KA, Strong AC, Kaiser Y, Marquering HA et al (2016) Thresholds for arterial wall inflammation quantified by (18)F-FDG PET imaging: implications for vascular interventional studies. JACC Cardiovasc Imaging 9(10):1198–1207

van der Valk FM, Kuik C, Verweij SL, Stiekema LCA, Kaiser Y, Zeerleder S et al (2017) Increased haematopoietic activity in patients with atherosclerosis. Eur Heart J 38(6):425–432

Yang X (2020) Multitissue multitomics systems biology to dissect complex diseases. Trends Mol Med 26(8):718–728

Yang Y, Sohn JH, Behr SC, Gullberg GT, Seo Y (2021) CT-less direct correction of attenuation and scatter in the image space using deep learning for whole-body FDG PET: potential benefits and pitfalls. Radiol Artif Intell 3(2):e200137

Zatcepin A, Pizzichemi M, Polesel A, Paganoni M, Auffray E, Ziegler SI et al (2020) Improving depth-of-interaction resolution in pixelated PET detectors using neural networks. Phys Med Biol 65(17):175017

Zukotynski K, Gaudet V, Uribe CF, Mathotaarachchi S, Smith KC, Rosa-Neto P et al (2021) Machine learning in nuclear medicine: part 2—neural networks and clinical aspects. J Nucl Med 62(1):22–29

Zwanenburg A (2019) Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. Eur J Nucl Med Mol Imaging 46(13):2638–2655

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com